Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors

Journal of Infectious Diseases

Volumn 203, Issue 1, 2011, Pages 25-31

  Pizzorno, Andrés ^a   Bouhy, Xavier ^a   Abed, Yacine ^a   Boivin, Guy ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; A 315675; OSELTAMIVIR; PERAMIVIR; SIALIDASE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG APPROVAL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INFLUENZA A (H1N1); MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANDEMIC INFLUENZA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRAL GENETICS; VIRUS CHARACTERIZATION; VIRUS MUTANT; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS RESISTANCE;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; CYCLOPENTANES; DRUG RESISTANCE, VIRAL; GUANIDINES; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; NEURAMINIDASE; OSELTAMIVIR; PLAQUE ASSAY; PYRROLIDINES; RECOMBINATION, GENETIC; VIRAL PROTEINS; VIRUS REPLICATION; ZANAMIVIR;

EID: 79851471047     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq010     Document Type: Article

References (41)

1. Abed Y, Boivin G. Treatment of respiratory virus infections. Antivir Res 2006; 70:1-16. (Pubitemid 43675656)
2. Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in adults and children-diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1003-32.
3. Abed Y, Nehmé B, Baz M, Boivin G. Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes. Antivir Res 2008; 77:163-6.
4. Abed Y, Simon P, Boivin G. Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation. Antimicrob Agents Chemother 2010; 54:2819-22.
5. BioCryst Pharmaceuticals, Inc. BioCryst's partner Shionogi receives marketing & manufacturing approval for peramivir in Japan Available at: http://investor.shareholder.com/biocryst/releasedetail.cfm?ReleaseID=437335. Accessed July 2010.
6. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20:127-33. (Pubitemid 32151932)
7. Wang MZ, Tai CY, Mendel DB. Mechanism by which mutations at his274 alter sensitivity of influenza a virus N1 neuraminidase to oseltamivir carboxylate and zanamivir. Antimicrob Agents Chemother 2002; 46:3809-16. (Pubitemid 35403254)
8. Weinstock DM, Gubareva LV, Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N Engl J Med 2003; 348:867-8. (Pubitemid 36245772)
9. Monto AS, McKimm-Breschkin JL, Macken C, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006; 50:2395-402. (Pubitemid 43993177)
10. Aoki FY, Boivin G, Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther 2007; 12:603-16. (Pubitemid 47235503)
11. Moscona A. Global transmission of oseltamivir-resistant influenza. N Engl J Med 2009; 360:953-6.
12. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: Descriptive study. Lancet 2004; 364:759-65. (Pubitemid 39165094)
13. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG. Recovery of drug-resistant influenza virus from immunocompromised patients: A case series. J Infect Dis 2006; 193:760-4.
14. Gubareva LV, Robinson MJ, Bethell RC, Webster RG. Catalytic and frameworkmutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 1997; 71:3385-90. (Pubitemid 27172346)
15. Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 2001; 183:523-31. (Pubitemid 32147507)
16. Centers for Disease Control and Prevention (CDC). Update: Influenza activity - United States, September 28, 2008-January 31, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:115-9.
17. Saad MD, Ahmed LS, Gamal-Eldein MA, et al. Possible avian influenza (H5N1) from migratory bird. Egypt. Emerg Infect Dis 2007; 13:1120-1. (Pubitemid 47048101)
18. Yen HL, Ilyushina NA, Salomon R, Hoffmann E, Webster RG, Govorkova EA. Neuraminidase inhibitor-resistant recombinant A/ Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. J Virol 2007; 81:12418-26. (Pubitemid 350085855)
19. Hurt AC, Holien JK, Barr IG. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob Agents Chemother 2009; 53:4433-40.
20. Le QM, Kiso M, Someya K, et al. Avian flu: Isolation of drug-resistant H5N1 virus. Nature 2005; 437:1108. (Pubitemid 41509341)
21. Dapat C, Suzuki Y, Saito R, et al. Rare influenza A (H3N2) variants with reduced sensitivity to antiviral drugs. Emerg Infect Dis 2010; 16:493-6.
22. Hurt AC, Holien JK, Parker M, Kelso A, Barr IG. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J Virol 2009; 83:10366-73.
23. Abed Y, Baz M, Boivin G. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir Ther 2006; 11:971-6. (Pubitemid 44955172)
24. World Health Organization (WHO). Pandemic (H1N1) 2009-update 103 Available at: http://www.who.int/csr/don/2010-06-04/en/index.html. Accessed June 2010.
25. World Health Organization (WHO). Update on oseltamivir-resistant pandemic A (H1N1) 2009 influenza virus: January 2010. Wkly Epidemiol Rec 2010; 85:37-48. http://www.who.int/wer/2010/wer8506/en/index.html. Accessed June 2010.
26. Liu Q, Wang S, Ma G, et al. Improved and simplified recombineering approach for influenza virus reverse genetics. J Mol Genet Med 2009; 3:225-31.
27. Hatakeyama S, Sakai-Tagawa Y, Kiso M, et al. Enhanced expression of an α-2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor. J Clin Microbiol 2005; 43:4139-46. (Pubitemid 41129710)
28. Potier M, Mameli L, Bélisle M, Dallaire L, Melançon SB. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-α- D-Nacetylneuraminate) substrate. Anal Biochem 1979; 94:287-96.
29. Baz M, Abed Y, Boivin G. Characterization of drug-resistant recombinant influenza A(H1N1) viruses selected in vitro with peramivir and zanamivir. Antivir Res 2007; 74:159-62. (Pubitemid 46436166)
30. Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 2005; 49:4515-20. (Pubitemid 41552580)
31. de Jong MD, Tran TT, Truong HK, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353:2667-72.
32. Centers for Disease Control and Prevention (CDC). Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis - North Carolina, 2009. MMWR Mortal Wkly Rep 2009; 58:969-72.
33. Chen H, Cheung CL, Tai H, et al. Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, China. Emerg Infect Dis 2009; 15:1970-2.
34. Baz M, Abed Y, Papenburg J, Bouhy X, Hamelin ME, Boivin G. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N Engl J Med 2009; 361:2296-7.
35. Memoli MJ, Hrabal RJ, Hassantoufighi A, Eichelberger MC, Taubenberger JK. Rapid selection of oseltamivir- and peramivirresistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis 2010; 50:1252-5.
36. Centers for Disease Control and Prevention (CDC). Oseltamivirresistant novel influenza A (H1N1) virus infection in 2 immunosuppressed patients - Seattle, Washington, 2009. MMWR Mortal Wkly Rep 2009; 58:893-6.
37. Le QM, Wertheim HF, Tran ND, van Doorn HR, Nguyen TH, Horby P. A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N Engl J Med 2010; 362:86-7.
38. Baz M, Abed Y, McDonald J, Boivin G. Characterization of multidrugresistant influenza A(H3N2) viruses shed during 1 year by an immunocompromised child. Clin Infect Dis 2006; 43:1555-61. (Pubitemid 44901897)
39. Collins PJ, Haire LF, Lin YP, et al. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 2008; 453:1258-61. (Pubitemid 351913590)
40. Gubareva LV. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res 2004; 103:199-203. (Pubitemid 38649080)
41. Zürcher T, Yates PJ, Daly J, et al. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro. J Antimicrob Chemother 2006; 58:723-32. (Pubitemid 44390944)